



ADIPONECTIN SERUM LEVELS IN ADOLESCENT BOYS WITH TYPE 1 DIABETES: RELATIONSHIPS TO PUBERTAL DEVELOPMENT, SEX HORMONE BINDING GLOBULIN AND TESTOSTERONE CONCENTRATIONS

Thesis

*Submitted for the Fulfillment of Ph.D. in Childhood Studies
Department of Medical Childhood Studies
(Child Health and Nutrition)*

Prepared by

Hussein Mohamed Abd El Rahman Abbas

M.B., B.Ch., M .Sc Pediatrics

Supervised by

Dr. Hayam Kamal Nazif

Professor of Pediatrics

Dean of Institute of Postgraduate Childhood Studies

Ain- Shams University

Dr. Laila Ibrahim Abou Basha

Professor of Clinical Chemistry

National Organization of Drug

Control and Research

Dr. Mohamed Hesham El Hefnawy

Professor of Diabetes and Endocrinology

Dean of National Institute of Diabetes and

Endocrinology

Institute of Postgraduate Childhood Studies

Ain Shams University

2016

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

"يُؤْتِي الْحِكْمَةَ مَنْ يَشَاءُ وَمَنْ يُؤْتَ
الْحِكْمَةَ فَقَدْ أُوتِيَ خَيْرًا كَثِيرًا وَمَا يَذَّكَّرُ
إِلَّا أُولُو الْأَلْبَابِ"

صدق الله العظيم

سوره البقره: الايه 269



Acknowledgment

*First of all, I would like to thank **Allah** for his grace and mercy and for giving me the effort to complete this work.*

*Special thanks to **Dr. Hayam Kamal Nazif** Professor of Pediatrics and Dean of Institute of Postgraduate Childhood Studies under whose supervision I had the honor and pleasure to proceed with this work. Her constant guidance encouragement and foresight made all the difference.*

*I would like to express my sincere thanks to **Dr. Mohamed Hesham El Hefnawy** Professor of Diabetes and Endocrinology and Dean of National Institute of Diabetes and Endocrinology for his kind help and valuable guidance, advice and supervision.*

*I would like to express my deepest gratitude to **Dr. Laila Ibrahim Abou Basha** Professor of Clinical Chemistry National Organization of Drug. Control and Research for her kind help and effort during preparation and completion of this work.*

Finally my deepest gratitude to my family for their sacrifices and encouragement.

Abstract

Background: Adiponectin is a protein hormone secreted exclusively by adipocytes that regulate the metabolism of lipids and glucose. Adiponectin has antidiabetic, antiatherogenic and anti-inflammatory properties. In addition it has an important protective role in carcinogenesis

OBJECTIVE: To assess adiponectin serum levels in adolescent boys with type 1 diabetes mellitus and to study the relationships between serum adiponectin levels with pubertal development body mass index, testosterone, sex hormone binding globulin and glycemic control.

Research design and methods: The study was a case- control study carried out on 45 adolescent boys with T1DM aged 12-18 years and 37 healthy control boys of similar age .The cases and controls were divided into four subgroups according to their pubertal stage (Tanner stage 2-5).They were subjected to full history, reviewing their medical records, and clinical examinations (Auxology, Blood pressure and Pubertal assessment). Serum total adiponectin level, total testosterone, sex hormone- binding globulin level and free testosterone level were determined by ELISA technique in addition to glycated haemoglobin and fasting blood glucose.

Results: Adiponectin serum level ($\pm$ SD) was significantly higher in T1DM boys compared to healthy control group ($12.93 \pm 5.24\mu\text{g/ml}$ versus $8.91 \pm 3.21\mu\text{g/ml}$) ($P < 0.001$).Such higher serum levels of adiponectin were detected mainly at Tanner stage 2 ($16.57 \pm 4.60\mu\text{g/ml}$ vs $11.88 \pm 3.39\mu\text{g/ml}$) ($P = 0.025$) and Tanner stage 3 ($12.77 \pm 3.71\mu\text{g/ml}$ vs $6.59 \pm 1.54\mu\text{g/ml}$) ($P = 0.002$). Adiponectin levels decreased

significantly during pubertal development in control group and T1DM group. The rate of decline in adiponectin serum level in T1DM boys was more smooth and regular in diabetic than control group. In T1DM boys adiponectin levels were negatively associated with pubertal stage, age, total testosterone, free testosterone, intermediate / long acting insulin dose and positively to HbA1c. No correlation was detected with SHBG or BMI. In control group adiponectin levels were negatively associated with pubertal stage, total testosterone and BMI.

Conclusion: Adiponectin serum levels in adolescent boys with type 1 diabetes were significantly higher than control mainly at early puberty. It decreases significantly during pubertal development and correlated negatively to pubertal stage, total and free testosterone levels, intermediate / long acting insulin dosage and positively to HbA1c .

Contents

	Page
List of Abbreviations	I
List of Tables	IV
List of Figures	VII
Introduction	1
Aim of the Work	3
Review of Literature	5
Chapter (1): Type 1 diabetes	5
Chapter (2): Adiponectin	79
Chapter (3): Pubertal development and sex hormones	110
Subject and Methods	150
Results	167
Discussion	218
Conclusion	276
Recommendations	277
Summary	279
References	288
Arabic Summary	----

List of Abbreviations

2-h PG	Two hours post prandial glucose
A1c - HbA1C	Glycated haemoglobin
ACEIs	Angiotensin-converting enzyme inhibitors
ACR	Albumin- creatinine ratio
ADA	American Diabetes Association
AdipoR	Adiponectin receptor
AMPK	Adenosine monophosphate kinase
ADPN	Adiponectin
APPL1	Adaptor protein containing a pleckstrin homology domain and a leucine zipper motif
ARBs	Angiotensin II receptor blockers
BGL	Blood glucose level
BM-HSC	Bone marrow-derived hematopoietic stem cell
BMI	Body mass index
CAD	Coronary artery disease
CB1	Cannabinoid -1 receptor
CGM	Continuous glucose monitoring
cIMT	Carotid intimal medial thickness
CRP	C- Reactive Protein
DAFNE	Dose Adjustment for Normal Eating study
DAISY	Diabetes Autoimmunity Study in the Young
DCCT	Diabetes control and complication trial
DD	Double diabetes
DHEA	Dehydroepiandrosterone
DHT	Dihydrotestosterone
DIA-PREV-IT	Diabetes Prevention-Immune Tolerance
DIPP	Diabetes Prediction and Prevention
DKA	Diabetic ketoacidosis
DN	Diabetic nephropathy
DPN	Diabetic polyneuropathy
DPT-1	Diabetes Prevention Trial–Type 1
DR	Diabetic retinopathy
DSCs	Adipose tissue-derived MSCs
EDIC	Epidemiology of Diabetes Interventions and Complications
ELISA	Enzyme-linked immunosorbent assay
ENDIT	The European Nicotinamide Diabetes Intervention Trial
ESCs	Embryonic stem cells
FAI	Free androgen index
FINDIA	Finnish Dietary Intervention Trial for the Prevention of T1DM

FPG	Fasting blood glucose
FSH	Follicle-stimulating hormone
GADA	Glutamic acid decarboxylase autoantibodies
GC	Genetic Consortium
GDM	Gestational diabetes mellitus
GFR	Glomerular filtration rate
GH	Growth hormone
GnRH	Gonadotropin releasing hormone
GPR54	KiSS-1 receptor
HDL	High- density lipoprotein
HIV/AIDS	Human Immunodeficiency Virus.
HLA	Human leucocyte antigen
HMW	High molecular weight
HNF	Hepatocyte nuclear factor
HOMA-IR	Homeostatic model of insulin resistance
HPA	Hypothalamic-pituitary-adrenal axis
HPG	Hypothalamic-pituitary-gonadal axis and
hs CRP	Highly sensitive CRP
IAA	Insulin autoantibodies
IA-2A	Insulinoma-2-associated autoantibodies
ICA	Islet cell cytoplasmic autoantibodies
IFG	Impaired fasting glucose
IGF-I	Insulin growth factor 1
IGT	Impaired glucose tolerance
IL-6	Interleukin 6
iPSCs	Induced pluripotent stem cells
IR	Insulin resistance
ISPAD	International Society for Pediatric and Adolescent Diabetes
JDRF	Juvenile Diabetes Research Foundation
KISS1	Kisspeptins gene
LADA	Latent autoimmune diabetes of adults
LDL	Low- density lipoprotein
LH	Luteinizing hormone
LMW	Low molecular weight
MAP	Mycobacterium avium subsp Paratuberculosis
MAP	Mean arterial pressure
MDI	Multiple daily injections
MHC	Major Histocompatibility Complex
MIH	Mullerian inhibiting hormone
MMW	Middle molecular weight
MODY	Maturity-Onset Diabetes of the Young

MS	Metabolic Syndrome
MSC	Mesenchymal stromal cell
NAFLD	Non -alcoholic fatty liver disease
NASH	Non- alcoholic steatohepatitis
NEFA	Non -Esterified fatty acid
NIH	National Institutes of Health
NO	Nitric oxide
NPH	Neutral Protamine Hagedorn Insulin
OGTT	Oral glucose tolerance test
ORPS	Oxford Regional Prospective Study
Ox LDL	Oxidized low density lipoprotein
PA	Physical activity
PCOS	polycystic ovarian syndrome
PHV	Peak height velocity
PPARα	Peroxisome-proliferator activated
RA	Rheumatoid arthritis
RAS	Renin-angiotensin system
ROS	Reactive-oxygen species
SEARCH	Search for Diabetes in Youth
SHBG	Sex hormone binding globulin
SIRT1	Sirtuin 1
SLE	Systemic lupus erythematosus
SMBG	Self-Monitoring of Blood Glucose
SMR	Sexual maturity rating
SNPs	Two single nucleotide polymorphisms
SREBP1c	Sterol regulatory element binding protein 1c
T2DM	Type 2 Diabetes Mellitus
T2-T3-T4- T5	Tanner stage 2-3-4-5
TDD	Total daily Dose
TG	Triglycerides
T1DM	Type 1 Diabetes Mellitus
TNFα	Tumor necrosis factor alpha
TZD	Thiazolidinedione
UCB-MSCs	Umbilical cord blood-derived MSCs
VAT	Visceral adipose tissues
WHR	Waist to hip ratio
ZnT8A	Zinc transporter

List of Tables

Table	Title	Page
1	Classification and clinical characteristics of diabetes mellitus	21
2	Criteria for the diagnosis of diabetes	21
3	Categories of increased risk for diabetes	22
4	Screening for micro- and macrovascular complications in youth with type 1 diabetes	34
5	Recommendations to reduce diabetic vascular complications	36
6	Clinical features in evaluation of a child with diabetic ketoacidosis (DKA)	40
7	Complications of DKA	43
8	Risk factors for severe hypoglycemia	45
9	Examples of carbohydrate for treatment of mild-to-moderate hypoglycemia	49
10	Plasma blood glucose and A1C goals for type 1 diabetes by age group	50
11	Types of insulin preparations and their pharmacokinetic parameters	51
12	Closed-loop approaches according to treatment objective	66
13	Energy intake recommendations	70
14	Sexual Maturity Rating	118
15	The diagnosis and differential diagnosis of normal variants and pathological types of puberty	122
16	Total Testosterone Reference Ranges	136
17	Reference Interval for sex hormone binding globulin in children and adolescents	145
18	Test procedure for assay of free testosterone	165
19	Comparison between control and diabetic groups as regards number of cases at various pubertal stages	167
20	comparison between control and diabetic group as regards demographic and clinical parameters	168
21	Comparison between control and diabetic groups as regards frequency of cases according to BMI, height and weight Egyptian percentiles	169
22	Comparison between control and diabetic as regards BMI according to Egyptian BMI percentile	170
23	Comparison between control and diabetic groups as regards laboratory parameters	170
24	Comparison between control and diabetic groups regarding adiponectin serum levels	171

25	Comparison between control and diabetic groups regarding SHBG serum levels	172
26	Comparison between control and diabetic groups regarding total testosterone serum levels	173
27	Comparison between control and diabetic groups regarding free testosterone serum levels	174
28	Comparison between control and diabetic groups as regards serum adiponectin level according to BMI percentile	175
29	Comparison between control , diabetic good glycemic control and diabetic poor glycemic control groups regarding glycated haemoglobin %	176
30	Comparison between control, diabetic good glycemic control, and diabetic poor glycemic control groups regarding serum adiponectin levels	176
31	Multiple Comparisons between control , diabetic good glycemic control and diabetic bad –glycemic control groups as regards serum adiponectin level	177
32	Comparison between diabetic groups as regards serum adiponectin level according to duration group	178
33	Comparison between control and diabetic groups as regards clinical and laboratory parameters at Tanner stage 2	179
34	Comparison between control and diabetic groups as regards clinical and laboratory parameters at Tanner stage 3	180
35	Comparison between control and diabetic groups as regards clinical and laboratory parameters at Tanner stage 4	181
36	Comparison between control and diabetic groups as regards clinical and laboratory parameters at Tanner stage 5	182
37	Comparison of adiponectin serum levels between control and diabetic groups at various pubertal stages	183
38	Comparison of SHBG serum levels between control and diabetic groups at various pubertal stages	184
39	Comparison of total testosterone serum levels between control and diabetic groups at various pubertal stages	185
40	Comparison of free testosterone serum level between control and diabetic at various pubertal stages	186
41	Variation in adiponectin serum level between pubertal stages in control group	186
42	Multiple Comparisons between pubertal stages in control groups regards adiponectin serum levels	186
43	Variation in adiponectin serum level between pubertal stages in diabetic group	188
44	Multiple Comparisons between pubertal stages in diabetic group as regards adiponectin serum levels	188
45	Variation in SHBG serum level between pubertal stages in control group	190

46	Multiple comparisons between pubertal stages in control group as regards SHBG serum levels	190
47	Variation in SHBG serum level between pubertal stages in diabetic group	191
48	Multiple comparisons between pubertal stages in diabetic group as regards SHBG serum levels	191
49	Variation in total testosterone serum between pubertal stages in control group	193
50	Comparisons between pubertal stages in control and diabetic groups as regards total testosterone levels	193
51	Variation in total testosterone serum level between pubertal stages in diabetic group	194
52	Comparisons between pubertal stages diabetic group as regards total testosterone levels	194
53	Variation in free testosterone serum level between various pubertal stages in control group	195
54	Comparisons between pubertal stages in control group as regards free testosterone levels	196
55	Variation in free testosterone serum level between various pubertal stages in diabetic group	196
56	Comparisons between pubertal stages in diabetic group as regards free testosterone levels	197
57	Variation in demographic and clinical parameters of the control group at various pubertal stages	198
58	variation in demographic and clinical parameters of the diabetic group at various pubertal stages	198
59	Variation in diabetic parameters between pubertal stages in diabetic group	199
60	Insulin type at various pubertal stages in the diabetic group	200
61	Insulin regimen at various pubertal stages in the diabetic group	200
62	Correlations of adiponectin in control group	201
63	Correlations of adiponectin in diabetic group	203
64	Correlations of SHBG in the control group	207
65	Correlations of SHBG in the diabetic group	208
66	Correlation of total testosterone in control group	210
67	Correlation of total testosterone in diabetic group	211
68	Correlation of free testosterone in control group	213
69	Correlation of free testosterone in diabetic group	214
70	Stepwise multiple regression analysis including control and T1DM boys with adiponectin as dependent variable	215
72	Stepwise multiple regression analysis of T1DM group with adiponectin as dependent variable	216
73	Stepwise multiple regression analysis of control group with adiponectin as dependent variable	217

List of Figures

Figure	Title	Page
1	Incidence rates of type 1 diabetes in children 0-14 years	5
2	Modern model of the pathogenesis and natural history of Type 1 diabetes.	9
3	Loci associated with risk of Type 1 diabetes	12
4	Type 1 diabetes risk stratification by islet autoantibody properties	16
5	Diagnostic criteria for T1A diabetes	18
6	Risk factors for the development of vascular complications in adolescents with type 1 diabetes	28
7	Algorithm for the Management of Diabetic Ketoacidosis	42
8	Example of a physiologic insulin delivery regimen	52
9	Representation of a closed-loop insulin delivery system.	65
10	Nine-year insulin independence and C-peptide islet graft function rates with the original Edmonton Protocol immunosuppression	67
11	Stem cell strategies for the cure of T1DM.	69
12	Structure and domains of adiponectin	80
13	Multimer formation of adiponectin	80
12	Adiponectin, adiponectin receptors and intracellular signaling.	83
13	Adiponectin hypothesis for insulin resistance, the metabolic syndrome, and atherosclerosis	105
14	Regulation of human puberty onset and progression via The HPG and the HPA axes	112
15	Relationship of key pubertal stages to pubertal growth velocity	120
16	Hypothalamic–pituitary–testicular axis	126
17	Crystal structure of SHBG protein	137
18	Plasma sex hormone-binding globulin levels in males and females from birth to old age	145
19	Comparison between control and diabetic groups as regards number of cases at various pubertal stages	167
20	Comparison between control and diabetic groups as regards adiponectin serum level	171
21	Comparison between control and diabetic groups as regards SHBG serum level	172

22	Comparison between control and diabetic groups regarding total testosterone serum levels	173
23	Comparison between control and diabetic groups regarding free testosterone serum levels	174
24	Comparison between control and diabetic groups as regards serum adiponectin level according to BMI percentile	175
25	Adiponectin serum levels in control and diabetic groups according to glycemic control	177
26	Comparison between diabetic groups as regards serum diponectin level according to duration group	178
27	Comparison of adiponectin serum levels between control and diabetic groups at various pubertal stages	183
28	Comparison of SHBG serum levels between control and diabetic groups at various pubertal stages	184
29	Comparison of total testosterone serum levels between control and diabetic groups at various pubertal stages	185
30	Comparison of free testosterone serum level between control and diabetic at various pubertal stages	186
31	Variation in adiponectin serum level during pubertal development in control and diabetic groups	189
32	Variation in SHBG levels during pubertal development in control and diabetic groups	192
33	Variation in total testosterone levels during pubertal development in control and diabetic group	195
34	Variation in free testosterone levels during pubertal development in control and diabetic group	197
35	Correlation of adiponectin to total testosterone in control group	202
36	Correlation of adiponectin to body mass index in control group	202
37	Correlation of adiponectin to glycated haemoglobin in diabetic group	204
38	Correlation of adiponectin to dose of intermediate/ long acting insulin in the diabetic group	204
39	Correlation of adiponectin to total testosterone in diabetic group	205
40	Correlation of adiponectin and free testosterone in diabetic group	205
41	Correlation of adiponectin to diastolic blood pressure in diabetic group	206



INTRODUCTION

Diabetes mellitus is a serious chronic disorder of childhood and represents a major public health problem. Type 1 diabetes is the predominant form of diabetes during childhood and adolescence, accounting for about 90% of cases (**Craig et al., 2009; Patterson et al., 2009**). The global incidence of type 1 diabetes is increasing worldwide, at an annual rate of 3-5%, particularly in children under the age of 5 years, and this trend leads to a significant health burden (**Patterson et al., 2009**).

Pubertal development is characterized by many physiological changes, involving both hormonal and metabolic processes, and these factors together with psychological issues are frequently responsible for poor glycaemic control. Treatment may be complicated by poor compliance, difficulties in targeting insulin therapy and concerns about weight gain (**Dunger, 1992**).

Adiponectin is a protein hormone secreted exclusively by adipocytes that regulate the metabolism of lipids and glucose (**Savino et al., 2008**). Among adipokines, adiponectin has gained considerable attention because of its antidiabetic, antiatherogenic and anti-inflammatory properties. Interest in adiponectin has increased significantly with demonstration that it has an important protective role in carcinogenesis (**Barb et al., 2007**).

Studies in adolescents have documented that pubertal development has an effect on adiponectin serum levels and that gender difference in adiponectin develop during pubertal development and sex steroids may be